3 results
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…
Approved WMOCompleted
To determine the optimal patient observation and Avastin injection schedule.
Approved WMORecruiting
The purpose of this trial is to determine the safety and efficacy of TAVR via a transfemoral approach in HF patients with moderate AS as compared with OHFT with regard to the composite of death, stroke, hospital admissions, symptoms, functional…